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Maintaining the genomic stability of both normal cells and cancer cells depends on coordinated 
networks of different forms of the DNA damage response, which execute various cell activities 
such as cell-cycle arrest, apoptosis, and premature senescence. Abrogation of these systems likely 
leads to extensive genomic instability and subsequent cell death upon DNA damage. CBP-93872 
was previously identified as a G2 checkpoint inhibitor using a cell-based high-throughput screening 
system. However, its molecular actions as well as cellular targets are largely unknown. Here, we 
uncovered the molecular mechanisms underlying abrogation of the G2 checkpoint by CBP-93872. 
CBP-93872 specifically abrogates the DNA double-stranded break (DSB)–induced G2 checkpoint 
through inhibiting maintenance but not initiation of G2 arrest because of specific inhibition of DSB-
dependent ATR activation. Hence, ATR-dependent phosphorylation of Nbs1 and replication protein 
A 2 upon DSB was strongly suppressed in the presence of CBP-93872. CBP-93872 did not seem to 
inhibit DNA-end resection, but did inhibit Nbs1-dependent and ssDNA-induced ATR activation in 
vitro in a dose-dependent manner. Taken together, our results suggest that CBP-93872 is an 
inhibitor of maintenance of the DSB-specific G2 checkpoint and thus might be a strong candidate as 
the basis for a drug that specifically sensitizes p53-mutated cancer cells to DSB-inducing DNA 
damage therapy.  
